Limited family structure and BRCA gene mutation status in single cases of breast cancer.
暂无分享,去创建一个
Julie O. Culver | J. Weitzel | K. Blazer | D. Macdonald | J. Culver | P. Gambol | Melanie R Palomares | K. Lowstuter | Jeffrey N Weitzel | C. Cullinane | Kathleen R Blazer | Deborah J MacDonald | Veronica I Lagos | Carey A Cullinane | Patricia J Gambol | Julie O Culver | Katrina J Lowstuter | M. Palomares | V. Lagos
[1] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.
[2] J. Weitzel,et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. , 2003, Archives of surgery.
[3] J. Satagopan,et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[5] Adopted on March. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Skolnick,et al. Statement of the American Society of Clinical Oncology : Genetic testing for cancer susceptibility. Commentaries , 1996 .
[8] S. Seal,et al. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Sean V Tavtigian,et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Sellers,et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Mills,et al. Assessing BRCA carrier probabilities in extended families. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] O. Olopade,et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. , 2005, Gynecologic oncology.
[14] C. Magnant,et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. King,et al. Inherited predisposition to breast and ovarian cancer. , 1994, American journal of human genetics.
[16] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[17] C B Begg,et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[18] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[19] N. Rahman,et al. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing , 2005, Journal of Medical Genetics.
[20] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[21] J. Andersen,et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. , 2000, American journal of surgery.
[22] J. Elmore,et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N E Day,et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.
[24] J. Weitzel. Genetic cancer risk assessment , 1999, Cancer.
[25] N. Rahman,et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO , 2004, Journal of Medical Genetics.
[26] D. Easton,et al. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families , 2005, Breast Cancer Research.
[27] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[28] R. Tollenaar,et al. MRI screening for breast cancer in women with high familial and genetic risk: First results of the Dutch MRI screening study (MRISC). , 2003 .
[29] S. Schnitt,et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] B. Mukesh,et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. C. Lee,et al. The Importance of Paternal Family History in Hereditary Breast Cancer Is Underappreciated by Health Care Professionals , 2003, Oncology.
[32] Ellen Warner,et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.
[33] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[34] U. P. S. T. Force. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement , 2005, Annals of Internal Medicine.
[35] Ellen Warner,et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] B. Weber,et al. Application of breast cancer risk prediction models in clinical practice. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Susan L Neuhausen,et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Easton,et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.